Investigational drug · Phase 3
DA-302168S
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Overweight and Obesity, Type 2 Diabetes Mellitus.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
9
Any phase or sponsor naming "DA-302168S"
First trial start
2025
May 15, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DA-302168S", any sponsor or status.
Conditions studied
As listed on its trial records.
- Overweight and Obesity
- Type 2 Diabetes Mellitus
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "DA-302168S" as an intervention, largest first.
- A Study of DA-302168S in Participants With Overweight/ObesityPivotal-lookingRecruiting
Chendu DIAO Pharmaceutical Group CO., LTD.Industry
NCT07629544 · 840 participants (planned) · Start Jun 19, 2026 · Primary completion Jul 9, 2027
Drug: DA-302168S; DA-302168S and 1 more · For: Overweight and Obesity
Sites: Beijing, China
- A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 DiabetesPivotal-lookingNot yet recruiting
Chendu DIAO Pharmaceutical Group CO., LTD.Industry
NCT07755150 · 272 participants (planned) · Start Aug 30, 2026 · Primary completion Oct 20, 2027
Drug: DA-302168S; Placebo of DA-302168S · For: Type 2 Diabetes Mellitus
Sites: Beijing, China
- A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese SubjectsPivotal-lookingCompleted
Chendu DIAO Pharmaceutical Group CO., LTD.Industry
NCT06953063 · 250 participants · Start May 15, 2025 · Primary completion Dec 15, 2025
Drug: DA-302168S; Placebo of DA-302168S · For: Overweight and Obesity
Sites: Beijing, China
Chendu DIAO Pharmaceutical Group CO., LTD.Industry
NCT06534320 · 50 participants · Start Apr 18, 2024 · Primary completion Dec 31, 2024
Drug: DA-302168S; Placebo of DA-302168S and 2 more · For: Overweight and Obesity
Sites: Nanjing, China
Chendu DIAO Pharmaceutical Group CO., LTD.Industry
NCT06541730 · 48 participants · Start Aug 30, 2024 · Primary completion Jan 30, 2025
Drug: DA-302168S; Placebo of DA-302168S · For: Overweight and Obesity
Sites: Hefei, China
Chendu DIAO Pharmaceutical Group CO., LTD.Industry
NCT07938515 · 32 participants (planned) · Start Nov 2, 2026 · Primary completion Dec 12, 2026
Drug: DA-302168S · For: Obesity & Overweight
Sites: Suzhou, China
- Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Hepatic Impairment and Normal Hepatic FunctionNot yet recruiting
Chendu DIAO Pharmaceutical Group CO., LTD.Industry
NCT07877038 · 32 participants (planned) · Start Oct 22, 2026 · Primary completion Apr 7, 2027
Drug: DA-302168S · For: Obesity, Overweight; T2DM (Type 2 Diabetes Mellitus)
Chendu DIAO Pharmaceutical Group CO., LTD.Industry
NCT06534346 · 16 participants · Start Jul 18, 2024 · Primary completion Aug 3, 2024
Drug: 15 mg DA-302168S tablet · For: Overweight and Obesity
Sites: Nanjing, China
Chendu DIAO Pharmaceutical Group CO., LTD.Industry
NCT07857265 · 10 participants (planned) · Start Nov 20, 2026 · Primary completion Dec 20, 2026
Drug: [14C] DA-302168S · For: Healthy Adult Subjects
Newest research
PubMed records naming it or its code names, newest first.
- Oral Small-Molecule GLP-1 Receptor Agonists: Lessons from Clinical Candidates and a Blueprint for Next-Generation Design.
Hu J, Zhang Y, Wang M, et al. · J Med Chem 2026
- Phase I study of the oral GLP-1 receptor agonist DA-302168S: Safety, pharmacokinetics, and pharmacodynamics in healthy and overweight/obese adults.
Zheng L, Yang Y, Dong G, et al. · Diabetes Obes Metab 2025
- Discovery and Evaluation of DA-302168S as an Efficacious Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist.
Dong G, Ye Q, Li W, et al. · J Med Chem 2025
Also in development for Overweight and Obesity
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- LenbelintideAZD6234Phase 39 trials
AstraZeneca · Obesity or Overweight, Obesity, Overweight
- MazdutideLY3305677Phase 35 trials
Eli Lilly · Type 2 Diabetes, Obesity, Overweight
- HDM1002Phase 34 trials
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Type 2 Diabetes, Overweight and Obesity
- AZD9550Phase 23 trials
AstraZeneca · Overweight and Obesity, Obesity/Overweight, Obesity or Overweight
- TE-8105 MADPhase 22 trials
Immunwork, Inc. · Overweight and Obesity
- CPX101Phase 21 trial
Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd. · Overweight and Obesity
- WVE-007Phase 21 trial
Wave Life Sciences USA, Inc. · Overweight and Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.